Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
PRLD logo PRLD
Upturn stock ratingUpturn stock rating
PRLD logo

Prelude Therapeutics Inc (PRLD)

Upturn stock ratingUpturn stock rating
$1.31
Last Close (24-hour delay)
Profit since last BUY24.76%
upturn advisory
Consider higher Upturn Star rating
BUY since 7 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/28/2025: PRLD (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

4 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $3.5

1 Year Target Price $3.5

Analysts Price Target For last 52 week
$3.5 Target price
52w Low $0.61
Current$1.31
52w High $5.53

Analysis of Past Performance

Type Stock
Historic Profit -30.23%
Avg. Invested days 29
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/28/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 72.45M USD
Price to earnings Ratio -
1Y Target Price 3.5
Price to earnings Ratio -
1Y Target Price 3.5
Volume (30-day avg) 4
Beta 1.21
52 Weeks Range 0.61 - 5.53
Updated Date 08/29/2025
52 Weeks Range 0.61 - 5.53
Updated Date 08/29/2025
Dividends yield (FY) -
Basic EPS (TTM) -1.64

Earnings Date

Report Date 2025-08-14
When -
Estimate -0.48
Actual -0.41

Profitability

Profit Margin -
Operating Margin (TTM) -1928.67%

Management Effectiveness

Return on Assets (TTM) -49.75%
Return on Equity (TTM) -96.33%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 17149441
Price to Sales(TTM) 10.35
Enterprise Value 17149441
Price to Sales(TTM) 10.35
Enterprise Value to Revenue 2.45
Enterprise Value to EBITDA -0.54
Shares Outstanding 43750100
Shares Floating 29179176
Shares Outstanding 43750100
Shares Floating 29179176
Percent Insiders 11.34
Percent Institutions 62.34

ai summary icon Upturn AI SWOT

Prelude Therapeutics Inc

stock logo

Company Overview

overview logo History and Background

Prelude Therapeutics Inc. was founded in 2016 and is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting chromatin regulation, an area of cancer biology involved in gene expression control.

business area logo Core Business Areas

  • PRMT5 Inhibitors: Focuses on developing PRMT5 inhibitors, such as PRT543 and PRT811, for hematologic malignancies and solid tumors.
  • SMARCA2 Degrader: Developing a SMARCA2 degrader for specific cancers.

leadership logo Leadership and Structure

Dr. Kris Vaddi is the CEO. The company has a board of directors and a management team overseeing research, development, clinical operations, and business development.

Top Products and Market Share

overview logo Key Offerings

  • PRT543: PRT543 is an oral, selective inhibitor of protein arginine methyltransferase 5 (PRMT5) being developed for genetically defined cancers, including solid tumors. The company is focusing on biomarker-selected patients. Competitors include companies developing other PRMT5 inhibitors, such as Novartis and GSK.
  • PRT811: PRT811 is an oral, selective PRMT5 inhibitor being developed for hematologic malignancies. Competitors include companies developing other PRMT5 inhibitors, such as Novartis and GSK.

Market Dynamics

industry overview logo Industry Overview

The biopharmaceutical industry is characterized by high research and development costs, long development timelines, regulatory hurdles, and intense competition. The market for cancer therapeutics is large and growing, with increasing demand for targeted therapies.

Positioning

Prelude Therapeutics is positioned as a company focused on novel cancer targets and precision medicine. Its competitive advantage lies in its expertise in chromatin regulation and its pipeline of differentiated small molecule inhibitors.

Total Addressable Market (TAM)

The total addressable market for cancer therapeutics is estimated to be hundreds of billions of dollars. Prelude is targeting specific patient populations with unmet needs, aiming for a significant share within its focused areas.

Upturn SWOT Analysis

Strengths

  • Novel targets in chromatin regulation
  • Pipeline of differentiated small molecule inhibitors
  • Experienced management team
  • Focus on precision medicine

Weaknesses

  • Clinical-stage company with no approved products
  • High cash burn rate
  • Dependence on successful clinical trials
  • Limited commercial infrastructure

Opportunities

  • Positive clinical trial results
  • Partnerships with larger pharmaceutical companies
  • Expansion into new indications
  • Potential for breakthrough therapy designation

Threats

  • Clinical trial failures
  • Competition from other cancer therapies
  • Regulatory hurdles
  • Patent expirations
  • Market volatility

Competitors and Market Share

competitor logo Key Competitors

  • GILD
  • NVS
  • GSK
  • MRTX

Competitive Landscape

Prelude Therapeutics competes with large pharmaceutical companies and other biotech companies developing cancer therapies. Its advantage lies in its focus on novel targets and precision medicine, but it faces challenges in competing with companies with greater resources and established commercial infrastructure.

Growth Trajectory and Initiatives

Historical Growth: Historical growth is characterized by advancing preclinical programs into clinical trials and raising capital through public and private offerings.

Future Projections: Future growth is dependent on successful clinical trial outcomes and potential regulatory approvals. Analyst estimates vary based on the perceived likelihood of success.

Recent Initiatives: Recent initiatives include advancing PRT543 and PRT811 through clinical trials and exploring new indications for its pipeline candidates.

Summary

Prelude Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel cancer therapies. Its strength lies in its focus on chromatin regulation and differentiated small molecule inhibitors. The company is highly dependent on successful clinical trials and faces competition from larger pharmaceutical companies. Investors should watch for clinical trial updates and regulatory milestones.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Website
  • SEC Filings
  • Analyst Reports (estimates)

Disclaimers:

This analysis is for informational purposes only and should not be considered investment advice. Financial data may be estimated and subject to change. Market share data is approximated.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Prelude Therapeutics Inc

Exchange NASDAQ
Headquaters Wilmington, DE, United States
IPO Launch date 2020-09-25
Founder, CEO & Director Dr. Krishna Vaddi D.V.M., Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 131
Full time employees 131

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT3789, a selective degrader of SMARCA2 protein for the treatment of advanced or metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion; PRT7732, a selective and orally bioavailable SMARCA2 degraders to treat advanced or metastatic solid tumors; and PRT2527, a cyclin-dependent kinase 9 inhibitor for the treatment of advanced solid tumors. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC, and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.